Telehealth firms have sought to cash in on the popularity of GLP-1 drugs for weight loss, but a hefty new entrant could prove a bigger windfall for Novo and Lilly in obesity.
California picks generic drug company Civica to produce low-cost insulin
Insulin has come to embody the perversity of the U.S. health care system as list prices for the century-old drug, which 8.4 million Americans depend on for survival, quintupled over two decades to more than $300 for a single vial.